echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Twist Bioscience reached a final agreement on the acquisition of Abveris, which will enhance biopharmaceutical capabilities

    Twist Bioscience reached a final agreement on the acquisition of Abveris, which will enhance biopharmaceutical capabilities

    • Last Update: 2022-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    South San Francisco, California, USA - (Business Wire) - November 22, 2021 - Twist Bioscience (NASDAQ: TWST) is a company that uses its silicon-based platform to provide high-quality synthetic DNA to help customers A successful company, the company announced that it has reached a final agreement to acquire Abveris (formally known as AbX Biologics, Inc.


    Abveris uses its proprietary DiversimAb™ series of hyperimmune mouse models to provide comprehensive antibody discovery and characterization services.


    Dr.


    Tracey Mullen, CEO of Abveris, said: "We look forward to combining our proprietary in vivo discovery platform with Twist's lead optimization process to integrate and simplify the process, and identify the highest level that can be used immediately for development for our partners.


    The total purchase consideration of up to US$190 million includes the US$150 million consideration issued at the end of the transaction, including Twist common stock and a maximum of US$10 million in cash, subject to customary claims for cash, net working capital, outstanding debt, and outstanding debt.


    In this transaction, Edgemont Partners acted as Abveris's exclusive financial adviser, and Nutter, McClennen & Fish LLP acted as Abveris's legal adviser


    About Twist Bioscience


    Twist Bioscience is a leading and fast-growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to promote the industrialization of bioengineering



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.